Royal Bank of Canada
SPRY icon

Royal Bank of Canada’s ARS Pharmaceuticals SPRY Stock Holding History

Royal Bank of Canada’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21K Sell
2,616
-2,068
-44% -$19.8K ﹤0.01% 5884
2025
Q4 		$54K Sell
4,684
-33,432
-88% -$325K ﹤0.01% 5516
2025
Q3 		$383K Sell
38,116
-64,675
-63% -$928K ﹤0.01% 4675
2025
Q2 		$1.79M Buy
102,791
+84,244
+454% +$1.22M ﹤0.01% 3394
2025
Q1 		$234K Buy
18,547
+16,969
+1,075% +$204K ﹤0.01% 4584
2024
Q4 		$17K Sell
1,578
-3,964
-72% -$55.5K ﹤0.01% 6179
2024
Q3 		$80K Buy
5,542
+713
+15% +$8.48K ﹤0.01% 5481
2024
Q2 		$41K Buy
4,829
+2,640
+121% +$23.4K ﹤0.01% 5746
2024
Q1 		$23K Sell
2,189
-5,815
-73% -$43.4K ﹤0.01% 5863
2023
Q4 		$44K Buy
8,004
+4,162
+108% +$18.2K ﹤0.01% 6052
2023
Q3 		$15K Buy
3,842
+248
+7% +$1.63K ﹤0.01% 6286
2023
Q2 		$24K Buy
3,594
+3,589
+71,780% +$24K ﹤0.01% 6126
2023
Q1 		$0 Hold
5
– – ﹤0.01% 7451
2022
Q4 		$0 Buy
+5
New +$32 ﹤0.01% 7685
2022
Q2 		– Sell
-1,260
Closed -$4K – 7694
2022
Q1 		$4K Sell
1,260
-2,861
-69% -$12.5K ﹤0.01% 7337
2021
Q4 		$28K Buy
4,121
+1,781
+76% +$14.5K ﹤0.01% 6648
2021
Q3 		$23K Buy
2,340
+1,347
+136% +$33.2K ﹤0.01% 6636
2021
Q2 		$31K Sell
993
-165
-14% -$5.29K ﹤0.01% 6325
2021
Q1 		$51K Buy
+1,158
New +$54.8K ﹤0.01% 5867

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Royal Bank of Canada's SPRY Position: Q1 2026 in Review

Royal Bank of Canada reduced its ARS Pharmaceuticals (SPRY) stake by 44% in Q1 2026, selling an estimated $19.8K and leaving 2,616 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #5884.

Royal Bank of Canada first reported a position in SPRY in Q1 2021 and has held it in 19 quarters since. The position peaked at $1.79M in Q2 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Royal Bank of Canada held 2,616 shares of ARS Pharmaceuticals worth $21K as of Q1 2026.
  • Royal Bank of Canada sold 2,068 ARS Pharmaceuticals shares in Q1 2026, an estimated $19.8K.
  • ARS Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5884 holding.
  • Royal Bank of Canada first reported a position in ARS Pharmaceuticals in Q1 2021 and has held it in 19 quarters since.
  • Royal Bank of Canada's ARS Pharmaceuticals position peaked at $1.79M in Q2 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.